(Q38242113)

31 August 2017

title

Induced Pluripotent Stem Cells for Disease Modeling and Drug Discovery in Neurodegenerative Diseases (English)

1 reference

31 August 2017

1 reference

1 reference

Jin-Tai Yu

5

0 references

Lan Tan

series ordinal

2

object named as

Lan Tan

1 reference

31 August 2017

3

Teng Jiang

1 reference

31 August 2017

Lei Cao

1

1 reference

31 August 2017

Xi-Chen Zhu

series ordinal

4

1 reference

31 August 2017

publication date

23 August 2014

1 reference

31 August 2017

published in

Molecular Neurobiology

1 reference

31 August 2017

volume

52

1 reference

31 August 2017

issue

1

1 reference

31 August 2017

page(s)

244-255

1 reference

https://scigraph.springernature.com/pub.10.1007/s12035-014-8867-6

31 August 2017

exact match

0 references

cites work

A small molecule screen in stem-cell-derived motor neurons identifies a kinase inhibitor as a candidate therapeutic for ALS.

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Foreword: neurodegenerative diseases: challenges and opportunities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Modeling human neurological disorders with induced pluripotent stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Guidelines and techniques for the generation of induced pluripotent stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Impact of induced pluripotent stem cells on the study of central nervous system disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Induced pluripotent stem cells: from Nobel Prizes to clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Reprogramming of mouse and human cells to pluripotency using mature microRNAs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Using human pluripotent stem cells to untangle neurodegenerative disease mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Steps toward safe cell therapy using induced pluripotent stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Human stem cell models of neurodegeneration: a novel approach to study mechanisms of disease development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Induced neural stem cells (iNSCs) in neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Amniocytes can serve a dual function as a source of iPS cells and feeder layers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Embryonic stem cell and induced pluripotent stem cell: an epigenetic perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Upping the ante: recent advances in direct reprogramming

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Generation of stable pluripotent stem cells from NOD mouse tail-tip fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Mechanism and methods to induce pluripotency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Assessing the risks of genotoxicity in the therapeutic development of induced pluripotent stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Muse cells and induced pluripotent stem cell: implication of the elite model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Human induced pluripotent stem cells and neurodegenerative disease: prospects for novel therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Cell reprogramming: expectations and challenges for chemistry in stem cell biology and regenerative medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

What can pluripotent stem cells teach us about neurodegenerative diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

The promise of induced pluripotent stem cells in research and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

How far are induced pluripotent stem cells from the clinic?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Potential therapeutic applications of differentiated induced pluripotent stem cells (iPSCs) in the treatment of neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Modeling Parkinson's disease using induced pluripotent stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Modelling familial dysautonomia in human induced pluripotent stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Accelerating progress in induced pluripotent stem cell research for neurological diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Concise review: Can stem cells be used to treat or model Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Remodeling neurodegeneration: somatic cell reprogramming-based models of adult neurological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Efficient derivation of cortical glutamatergic neurons from human pluripotent stem cells: a model system to study neurotoxicity in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Primary skin fibroblasts as a model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion-associated phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Huntington's disease: dancing in a dish

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Inhibition of mitochondrial fragmentation diminishes Huntington's disease-associated neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

miR-196a ameliorates phenotypes of Huntington disease in cell, transgenic mouse, and induced pluripotent stem cell models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Human pluripotent stem cells in drug discovery and predictive toxicology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Drug discovery in Parkinson's disease-Update and developments in the use of cellular models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Drug screening for ALS using patient-specific induced pluripotent stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Effectiveness of antidementia drugs in delaying Alzheimer's disease progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Epidemiology and etiology of Alzheimer's disease: from genetic to non-genetic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

CR1 in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Induced pluripotent stem cells as tools for disease modelling and drug discovery in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Novel disease-modifying therapies for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Progress toward the clinical application of patient-specific pluripotent stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Harnessing the potential of induced pluripotent stem cells for regenerative medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Induced pluripotent stem cells--opportunities for disease modelling and drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

The role of induced pluripotent stem cells in regenerative medicine: neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Alzheimer's disease modeling: ups, downs, and perspectives for human induced pluripotent stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

A human stem cell model of early Alzheimer's disease pathology in Down syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Identification and rescue of α-synuclein toxicity in Parkinson patient-derived neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Stem cells as in vitro model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Neural stem cells: mechanisms and modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

In vitro neurogenesis: development and functional implications of iPSC technology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

The iPS technique provides hope for Parkinson's disease treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Progress on stem cell research towards the treatment of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Redefining Parkinson's disease research using induced pluripotent stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

The evolving field of induced pluripotency: recent progress and future challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Human iPSC-based modeling of late-onset disease via progerin-induced aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Inducing cellular aging: enabling neurodegeneration-in-a-dish

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Genetic correction of Huntington's disease phenotypes in induced pluripotent stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Neuronal properties, in vivo effects, and pathology of a Huntington's disease patient-derived induced pluripotent stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Human pluripotent stem cell therapy for Huntington's disease: technical, immunological, and safety challenges human pluripotent stem cell therapy for Huntington's disease: technical, immunological, and safety challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Disease modeling and drug screening for neurological diseases using human induced pluripotent stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Identification of anti-inflammatory targets for Huntington's disease using a brain slice-based screening assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Cellular therapy and induced neuronal replacement for Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Amyotrophic lateral sclerosis-related VAPB P56S mutation differentially affects the function and survival of corticospinal and spinal motor neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Neurodegenerative disease-specific induced pluripotent stem cell research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Reprogramming therapeutics: iPS cell prospects for neurodegenerative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Induced pluripotent stem cells in the study of neurological diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Stem cell models for drug discovery and toxicology studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

MicroRNAs: novel therapeutic targets in neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Stem cell derived basal forebrain cholinergic neurons from Alzheimer's disease patients are more susceptible to cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Induced pluripotent stem cells: the new patient?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Emerging targets and treatments in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Modeling Huntington's disease with induced pluripotent stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Pathogenic mutation of ALK2 inhibits induced pluripotent stem cell reprogramming and maintenance: mechanisms of reprogramming and strategy for drug identification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Pluripotent stem cell for modeling neurological diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Induced pluripotent stem cells in cardiovascular drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

iPSC-derived neurons as a higher-throughput readout for autism: promises and pitfalls

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Small molecule screening in human induced pluripotent stem cell-derived terminal cell types

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Patient-derived stem cells: pathways to drug discovery for brain diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Genome-wide expression profiling and functional characterization of SCA28 lymphoblastoid cell lines reveal impairment in cell growth and activation of apoptotic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Isogenic human iPSC Parkinson's model shows nitrosative stress-induced dysfunction in MEF2-PGC1α transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

High content screening in neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Chemical genetics and drug screening in Drosophila cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Experimental models for identifying modifiers of polyglutamine-induced aggregation and neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Therapy development in spinal muscular atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

High-content genome-wide RNAi screens identify regulators of parkin upstream of mitophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Toward pluripotency by reprogramming: mechanisms and application

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Induced pluripotent stem cells: origins, applications, and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Present state and future perspectives of using pluripotent stem cells in toxicology research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Introduction to thematic minireview series: Development of human therapeutics based on induced pluripotent stem cell (iPSC) technology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Induced pluripotent stem cells as a model for accelerated patient- and disease-specific drug discovery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

The potential of induced pluripotent stem cells as a translational model for neurotoxicological risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

iPSCs and small molecules: a reciprocal effort towards better approaches for drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Human induced pluripotent stem cells and their use in drug discovery for toxicity testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Biomedical and clinical promises of human pluripotent stem cells for neurological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Opportunities and challenges of pluripotent stem cell neurodegenerative disease models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Can controlled cellular reprogramming be achieved using microRNAs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Future perspective of induced pluripotent stem cells for diagnosis, drug screening and treatment of human diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Induced pluripotent stem cells: past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Cellular reprogramming: a small molecule perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Adenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Generation of transgene-free induced pluripotent mouse stem cells by the piggyBac transposon

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Induced pluripotent stem cells: a new revolution for clinical neurology?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Hepatic transforming growth factor beta gives rise to tumor-initiating cells and promotes liver cancer development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

The path from skin to brain: generation of functional neurons from fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Cell transplantation therapies for spinal cord injury focusing on induced pluripotent stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

An introduction to induced pluripotent stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Current status of drug screening and disease modelling in human pluripotent stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Epigenomics of human embryonic stem cells and induced pluripotent stem cells: insights into pluripotency and implications for disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8867-6

Induced pluripotent stem cells: how they will change the practice of cardiovascular medicine

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25146848

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Promises and challenges of stem cell research for regenerative medicine

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25146848

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Can stem-cell-derived models revolutionize drug discovery?

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25146848

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S12035-014-8867-6

1 reference

Dimensions Publication ID

31 August 2017

1009008606

0 references

1 reference